10160998Mechanomics: scoping potential for a new data modality in disease biomarker and target discovery.ActiveFeasibility StudiesInnovate UKSynLaia Innovations is set to bring mechanical dimension to human biology and drug discovery. Through our unique mechano-transcriptomics computational pipeline, we aim to directly address a significant unmet need in drug development arising from high therapy failure rates, partly due inadequate disease modelling and lack of tissue-scale data. Our innovation is an **AI-driven, patient-centric drug discovery platform leveraging mechanomics** as a novel data modality. This approach uniquely integrates spatial mechano-physical parameters with multi-modal omics data (such as spatial transcriptomics and proteomics) to generate **mechano-signatures and cell and tissue mechanical states in health and disease**. Unlike standard target discovery relying on genetic predictions from single-cell technologies, we obtain spatial multi-modal omics data from human samples for direct translation within the correct tissue context. This approach allows it to pinpoint **biomarkers and drug targets by analysing how tissue mechanics and molecular profiles change across health and disease**, focusing on therapeutic targets which are drivers of tissue mechanical states.